Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 12/20 | 0.88 |
| ▸ | PDE9A | O76083 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6681615 | 0.94 | KCNMA1 (1.00) | KCNMA1PDE9AKDM4EBCL6LMNA | |
| SCHEMBL6683225 | 0.83 | KCNMA1 (1.00) | KCNMA1PDE9AKDM4EL3MBTL1 | |
| SCHEMBL6686574 | 0.83 | KCNMA1 (0.66) | KCNMA1PDE9AKDM4EGRM4 | |
| SCHEMBL6694339 | 0.82 | KCNMA1 (1.00) | KCNMA1PDE9AKDM4EBCL6 | |
| SCHEMBL6686443 | 0.82 | KCNMA1 (1.00) | KCNMA1PDE9AKDM4EBCL6 | |
| SCHEMBL6687522 | 0.82 | KCNMA1 (1.00) | KCNMA1PDE9AKDM4EBCL6 | |
| SCHEMBL6685596 | 0.82 | KCNMA1 (1.00) | KCNMA1PDE9AKDM4EBCL6 | |
| SCHEMBL6690770 | 0.80 | KCNMA1 (0.78) | KCNMA1PDE9A | |
| SCHEMBL6687702 | 0.79 | KCNMA1 (0.77) | KCNMA1PDE9A | |
| SCHEMBL6690456 | 0.78 | KCNMA1 (1.00) | KCNMA1PDE9AKDM4EPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122218-A1 | Pyrrolopyridine potassium channel openers | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122218-A1 | Pyrrolopyridine potassium channel openers | KCNJ2, KCNN1, KCNN2 | KCNMA1 12/4885PDE9A 1831/4885KDM4E 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.